First Light Asset Management LLC Raises Stake in Enzo Biochem, Inc. (ENZ)

First Light Asset Management LLC increased its position in Enzo Biochem, Inc. (NYSE:ENZ) by 5.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 251,002 shares of the medical research company’s stock after buying an additional 13,948 shares during the period. First Light Asset Management LLC owned 0.53% of Enzo Biochem worth $1,375,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. A.R.T. Advisors LLC acquired a new stake in shares of Enzo Biochem in the 1st quarter valued at about $115,000. Stone Ridge Asset Management LLC acquired a new stake in shares of Enzo Biochem in the 4th quarter valued at about $135,000. Trexquant Investment LP acquired a new stake in shares of Enzo Biochem in the 1st quarter valued at about $145,000. MetLife Investment Advisors LLC acquired a new stake in shares of Enzo Biochem in the 4th quarter valued at about $179,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Enzo Biochem in the 4th quarter valued at about $181,000. Institutional investors own 67.08% of the company’s stock.

Separately, ValuEngine downgraded Enzo Biochem from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st.

Enzo Biochem opened at $5.98 on Thursday, Marketbeat Ratings reports. Enzo Biochem, Inc. has a 52-week low of $5.35 and a 52-week high of $12.04.

Enzo Biochem (NYSE:ENZ) last released its quarterly earnings results on Tuesday, June 12th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.04). The company had revenue of $25.63 million for the quarter. Enzo Biochem had a negative net margin of 4.12% and a negative return on equity of 6.27%.

Enzo Biochem Profile

Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.

Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply